| dc.contributor | Balderas-Pea, L.-M.-A., UMAE Hospital de Especialidades Del Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Departamento de Farmacobiología, México, D.F., Mexico; Sat-Muoz, D., Instituto Mexicano Del Seguro Social, Departamento de Morfología, Centro Universitario de Ciencias de la Salud, México, D.F., Mexico; Contreras-Hernández, I., Unidad de Investigación en Economía de la Salud, Centro Médico Nacional Siglo XXI, Instituto Mexicano Del Seguro Social, México, D.F., Mexico; Solano-Murillo, P., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Hernández-Chávez, G.-A., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Mariscal-Ramírez, I., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Lomelí-García, M., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Díaz-Cortés, M.-A., Unidad de Investigación y Estudios de Posgrado, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, México, Mexico; Mould-Quevedo, J.-F., Instituto Tecnológico de Estudios Superiores de Monterrey, Campus Ciudad de México, Monterrey, Mexico; Palomares-Chacón, U., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Balderas-Pea, C.-A., Coloproctología, Hospital General Regional No. 110, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Garcés-Ruiz, O.-M., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico; Morgan-Villela, G., UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico | |
| dc.description.abstract | Introduction: In Mexico during 2008, were reported 127,604 new cancer cases, 6,347 of them were colorectal cancer cases and 4,276 Non-Hodgkin Lymphoma (NHL) cases. Objective: To Evaluate Health Related Quality of Life in Non-Hodgkin Lymphoma and colorectal cancer cases in different clinical stages, attended in a High Specialty Medical facility at the Instituto Mexicano del Seguro Social, during a 13 month period. Results: 162 patients were included, 56.8% (n=92) with NHL and 43.2% (n=70) with colorectal cancer. The scores obtained in the NHL group were: Global health status/QoL: 67.75 (±27.55), physical functioning 69.64 (±29.98), role functioning 71.38 (±33.73), emotional functioning 69.7 (±26.57), cognitive functioning 75.36 (±28.01), social functioning 79.35 (±29.38), fatigue 35.27 (±28.27), nausea and vomiting 13.41 (±21.85), pain 28.08 (±30.25), dyspnea 19.20 (±32.11), insomnia 30.80 (±38.03), appetite lost 26.45 (±36.16), constipation 19.20 (±32.11), diarrhea 12.32 (±26.48), financial difficulties 26.09 (±35.57). In colorectal cancer patients the scores were: Global health status/QoL: 68.21 (±24.46), physical functioning 67.38 (±30.45), role functioning 65.48 (±35.70), emotional functioning 66.43 (±26.84), cognitive functioning 78.57 (±26.49), social functioning 75.24 (±31.05), fatigue 37.78 (±31.62), nausea and vomiting 20.00 (±28.32), pain 37.38 (±34.45), dyspnea 11.90 (±26.64), insomnia 28.09 (±35.73), appetite lost 23.81 (±36.40), constipation 19.05 (±32.88), diarrhea 20.95 (±31.17), financial difficulties 34.76 (±38.67). Conclusions: With these basal results is important a follow-up with special attention to the treatment and attendance processes, in patients with this neoplasms and their impact on the quality of life. © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). | |
